Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.
Publication
, Journal Article
Antonia, SJ
Published in: N Engl J Med
March 7, 2019
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
N Engl J Med
DOI
EISSN
1533-4406
Publication Date
March 7, 2019
Volume
380
Issue
10
Start / End Page
990
Location
United States
Related Subject Headings
- Lung Neoplasms
- Humans
- General & Internal Medicine
- Chemoradiotherapy
- Carcinoma, Non-Small-Cell Lung
- Antibodies, Monoclonal
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Antonia, S. J. (2019). Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply. N Engl J Med, 380(10), 990. https://doi.org/10.1056/NEJMc1900407
Antonia, Scott J. “Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.” N Engl J Med 380, no. 10 (March 7, 2019): 990. https://doi.org/10.1056/NEJMc1900407.
Antonia SJ. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply. N Engl J Med. 2019 Mar 7;380(10):990.
Antonia, Scott J. “Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.” N Engl J Med, vol. 380, no. 10, Mar. 2019, p. 990. Pubmed, doi:10.1056/NEJMc1900407.
Antonia SJ. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply. N Engl J Med. 2019 Mar 7;380(10):990.
Published In
N Engl J Med
DOI
EISSN
1533-4406
Publication Date
March 7, 2019
Volume
380
Issue
10
Start / End Page
990
Location
United States
Related Subject Headings
- Lung Neoplasms
- Humans
- General & Internal Medicine
- Chemoradiotherapy
- Carcinoma, Non-Small-Cell Lung
- Antibodies, Monoclonal
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences